{"nctId":"NCT03931941","briefTitle":"Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)","startDateStruct":{"date":"2019-07-30","type":"ACTUAL"},"conditions":["Clostridium Difficile Infection","Infection","Communicable Diseases"],"count":793,"armGroups":[{"label":"Active","type":"EXPERIMENTAL","interventionNames":["Drug: RBX2660"]}],"interventions":[{"name":"RBX2660","otherNames":["Microbiota suspension"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. ≥ 18 years old.\n2. Medical record documentation of either: a) a current diagnosis or history of recurrent CDI as determined by the treating physician, b) or has had at least two episodes of severe CDI resulting in hospitalization.\n3. Is currently taking or was just prescribed antibiotics to control CDI related diarrhea at the time of enrollment. \\[Note: Subject's CDI diarrhea must be controlled (\\<3 unformed/loose stools/day) while taking antibiotics during screening.\\]\n\nExclusion Criteria:\n\n1. Has continued CDI diarrhea despite being on a course of antibiotics prescribed for CDI treatment.\n2. Requires systemic antibiotic therapy for a condition other than CDI.\n3. Fecal microbiota transplant (FMT) within the past 6 months.\n4. FMT with an associated serious adverse event related to the FMT product or procedure.\n5. Bezlotoxumab (CDI monoclonal antibodies) if received within the last year.\n6. CD4 count \\<200/mm\\^3 during Screening.\n7. An absolute neutrophil count of \\<1000 cells/µL during Screening.\n8. Pregnant, breastfeeding, or intends to become pregnant during study participation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety and Tolerability of RBX2660 in Subjects With Recurrent CDI.","description":"Number of subjects with investigational product- and/or enema-related treatment-emergent adverse events (TEAEs).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"697","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy of RBX2660 Measured at 8 Weeks After Treatment.","description":"The absence of C. difficile diarrhea without the need for retreatment through 8 weeks after administration of the study treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"499","spread":null}]}]}]},{"type":"SECONDARY","title":"Sustained Clinical Response Through 6 Months After Treatment.","description":"Treatment success of the presenting CDI recurrence and no new CDI episodes for greater than 8 weeks through 6 months after completing a study treatment assessed by subject phone interview up to 6 months after the last study treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"454","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":87,"n":697},"commonTop":["Diarrhoea","Abdominal pain","Nausea","Abdominal distension","Urinary tract infection"]}}}